预约演示
更新于：2025-11-03
Mitoxantrone Hydrochloride liposomal
盐酸米托蒽醌脂质体
更新于：2025-11-03
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2021-06-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、附条件批准 (中国) |
登录后查看时间轴
结构/序列
分子式C22H30Cl2N4O6 |
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N |
CAS号70476-82-3 |
关联
146
项与 盐酸米托蒽醌脂质体 相关的临床试验ChiCTR2500111610
A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL)
NCT07093710
The Safety and Efficacy of Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or GemOx in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study
ChiCTR2500111195
A prospective multicenter randomized controlled clinical study comparing the efficacy and safety of mitoxantrone hydrochloride liposomes with idarubicin in induction therapy for children with newly diagnosed acute myelocytic leukemia
100 项与 盐酸米托蒽醌脂质体 相关的临床结果
登录后查看更多信息
100 项与 盐酸米托蒽醌脂质体 相关的转化医学
登录后查看更多信息
100 项与 盐酸米托蒽醌脂质体 相关的专利（医药）
登录后查看更多信息
5,185
项与 盐酸米托蒽醌脂质体 相关的文献（医药）2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
A target-response ratiometric or turn-off fluorescent dual-mode platform for simultaneous detection of multiple anticancer drugs
Article
作者: Yu, Zhendi ; Feng, Da-Qian ; Fang, Bo ; Liu, Guoliang ; Li, Hengye ; Zhang, Wenfeng
The anthracycline including doxorubicin (DOX), daunorubicin (DAU) and mitoxantrone (MTX) plays crucial roles in human health due to their notably clinical efficacy in various malignant tumors. There is few molecular probe and abiotic sensor that can simultaneously discriminate among anthracycline drugs. Herein, a target-response ratiometric and turn-off fluorescent dual-mode platform was designed for simultaneous detection of multiple anticancer drugs based on blue-emitting carbon dots (BCDs). In the presence of anthracycline, specific absorption and formation of the BCDs-anthracycline conjugate was achieved via electrostatic interaction and hydrophobic force, leading to ratiometric signal or quenched fluorescent response, thereby achieving ratiometric or turn-off dual-mode detection. Specifically, the introduction of both DOX and DAU produce ratiometric response of BCDs due to fluorescence resonance energy transfer (FRET) and dynamic quenching while MTX only induce reduced fluorescent response attribute to photoinduced electron transfer (PET) and dynamic quenching. The linear range calculated is 1-98, 1-91 and 1-77 μM for DOX, DAU and MTX, respectively, with a limit of detection of 0.02, 0.05 and 0.06 μM. Taking advantage of target-response self-verification ratiometric and sensitive fluorescent detection, the dual-mode platform was proposed and applied for successful discrimination of anthracycline drugs. This study opens a new path for multiplex drugs analysis in a facile and rapid way.
2025-10-01ARTIFICIAL INTELLIGENCE IN MEDICINE
DDintensity: Addressing imbalanced drug-drug interaction risk levels using pre-trained deep learning model embeddings
Article
作者: Wang, Yuchen ; Zheng, Zetian ; Huang, Lei ; Peng, Chengbin ; Chen, Xingjian ; Xie, Weidun ; Wong, Ka-Chun ; Gullerova, Monika ; Zhang, Ruoxuan ; Liu, Zhichao ; Zhang, Xiao
Imbalanced datasets have been a persistent challenge in bioinformatics, particularly in the context of drug-drug interaction (DDI) risk level datasets. Such imbalance can lead to biased models that perform poorly on underrepresented classes. To address this issue, one strategy is to construct a balanced dataset, while another involves employing more advanced features and models. In this study, we introduce a novel approach called DDintensity, which leverages pre-trained deep learning models as embedding generators combined with LSTM-attention models to address the imbalance in DDI risk level datasets. We tested embeddings from various domains, including images, graphs, and textual corpus. Among these, embeddings generated by BioGPT achieved the highest performance, with an Area Under the Curve (AUC) of 0.97 and an Area Under the Precision-Recall curve (AUPR) of 0.92. Our model was trained on the DDinter and further validated using the MecDDI dataset. Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings.
2025-08-01ADVANCED FUNCTIONAL MATERIALS
An Endoplasmic Reticulum‐Targeting and Calcium Metabolism‐Disrupting Nanodrug Enhances Tumor Photodynamic Immunotherapy
作者: Liang, Shi‐Yu ; Xie, Yong‐Qi ; Liu, Li‐Han ; Liang, Xiao‐Feng ; Zou, Xin‐Ni ; Li, Chong ; Huang, Cheng‐Jie ; Jiaerheng, Gulijiayina
Abstract:
The inefficient clearance of deep tumors and metastatic lesions greatly hinders the clinical applications of photodynamic therapy (PDT). Inducing robust immunogenic cell death (ICD) is crucial for improving PDT outcomes, as ICD‐mediated T‐cell adaptive immune responses suppress tumor recurrence and metastasis. Sustained endoplasmic reticulum (ER) stress is essential for activating ICD, however, inadequate photosensitizer enrichment in the ER and cell‐protective mechanisms, such as the unfolded protein response (UPR) and antioxidant defense, often result in insufficient ER stress and ineffective ICD. To overcome these challenges, PPRK@MTO, a nanodrug co‐assembled from ER‐targeting chimeric peptide PpIX‐PEG8‐RKR‐KDEL (PPRK) and mitochondrial calcium uniporter (MCU) inhibitor mitoxantrone (MTO) is developed. Upon laser irradiation, PPRK generates reactive oxygen species (ROS) in situ, inducing strong ER stress and promoting ICD. Meanwhile, MTO inhibits MCU, reducing mitochondrial calcium influx and energy supply for UPR and glutathione biosynthesis, thereby amplifying PDT efficacy and enhancing ICD, inducing a strong antitumor immune response. PPRK@MTO demonstrats potent tumor suppression in vivo and prolonged survival in 4T1 tumor‐bearing mice with a single administration. This ER‐targeting and mitochondrial metabolism‐disrupting nanodrug provides a promising strategy for high‐efficiency photodynamic immunotherapy.
100 项与 盐酸米托蒽醌脂质体 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周T细胞淋巴瘤 | 中国 | 2021-06-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 鼻咽癌 | 临床3期 | 中国 | 2023-02-15 | |
| 复发性鼻咽癌 | 临床3期 | - | 2023-02-01 | |
| 难治性外周T细胞淋巴瘤 | 临床3期 | 中国 | 2021-04-14 | |
| 鼻咽肿瘤 | 临床2期 | - | 2025-04-01 | |
| 髓系肿瘤 | 临床2期 | 中国 | 2024-02-29 | |
| 难治性急性髓细胞白血病 | 临床2期 | 中国 | 2024-02-29 | |
| 复发性急性髓细胞白血病 | 临床2期 | 中国 | 2024-02-29 | |
| 复发性弥漫性大B细胞淋巴瘤 | 临床2期 | 中国 | 2023-07-27 | |
| 难治性弥漫性大 B 细胞淋巴瘤 | 临床2期 | 中国 | 2023-07-27 | |
| 视神经脊髓炎 | 临床2期 | 中国 | 2022-11-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 7 | 衊窪襯餘願獵鹽齋築襯(築糧齋糧夢鏇艱簾鹽壓) = 願觸願範願鏇餘築廠顧 簾憲襯觸鹽鹽壓廠遞淵 (衊艱鏇鹹憲襯艱夢願鹹 ) 更多 | 不佳 | 2025-05-30 | |||
衊窪襯餘願獵鹽齋築襯(築糧齋糧夢鏇艱簾鹽壓) = 蓋齋齋廠襯鏇齋壓憲壓 簾憲襯觸鹽鹽壓廠遞淵 (衊艱鏇鹹憲襯艱夢願鹹 ) | |||||||
临床1期 | 38 | Lipo-MIT combined with COP regimen | 繭獵衊壓網淵艱夢範遞(蓋壓壓壓糧糧製構構鏇) = 艱壓鏇築襯鹹艱窪選繭 餘鏇艱遞鹹齋繭衊鹽壓 (鏇壓鹽糧顧衊淵築獵襯, 73.3 ~ 96.8) 更多 | - | 2025-05-30 | ||
EHA2025 人工标引  | N/A | 17 | R-CDOPR-CMOP (rituximab 375 mg/m², D0; cyclophosphamide 750 mg/m², cisplatin 25 mg/m², vincristine 1.3 mg/m², D1; prednisone 100 mg, D1-5) switched to (liposomal mitoxantrone 18 mg/m²; other agents/doses identical to R-CDOP)rituximab 375 mg/m², D0; cyclophosphamide 750 mg/m², cisplatin 25 mg/m², vincristine 1.3 mg/m², D1; prednisone 100 mg, D1-5) switched to (liposomal mitoxantrone 18 mg/m²; other agents/doses identical to R-CDOP) | 鏇製膚糧製餘鏇醖遞鏇(糧淵製鑰艱築鑰淵獵醖) = After two R-CMOP cycles, 9 patients (52.9%) achieved complete response (CR), increasing to 12 (70.6% best response) after four cycles. 淵衊糧淵夢鹹獵淵衊遞 (築簾鑰齋鬱襯鬱鬱餘淵 ) 更多 | 积极 | 2025-05-14 | |
临床2期 | 11 | (favorable and intermediate risk) | 窪膚遞鹽觸鹹獵齋壓齋(糧觸鏇憲鹽衊憲襯積鏇) = 衊壓製遞築廠繭觸鏇簾 鹹襯遞鏇構艱蓋鬱鹽蓋 (鬱壓夢製憲顧構鏇願選 ) 更多 | 积极 | 2025-05-14 | ||
(adverse risk) | 窪膚遞鹽觸鹹獵齋壓齋(糧觸鏇憲鹽衊憲襯積鏇) = 窪製齋蓋積醖艱夢憲鹽 鹹襯遞鏇構艱蓋鬱鹽蓋 (鬱壓夢製憲顧構鏇願選 ) 更多 | ||||||
临床2期 | 非霍奇金淋巴瘤 一线 | 39 | CMOP±R regimen | 夢遞構衊積簾積膚網壓(顧簾窪積簾選鹹夢襯築) = 願鹽窪壓獵蓋鑰鹹願願 窪製獵襯壓鹹窪鹹夢選 (蓋範艱選願糧鏇遞簾簾 ) 更多 | 积极 | 2025-05-14 | |
R-CHOP | 夢遞構衊積簾積膚網壓(顧簾窪積簾選鹹夢襯築) = 廠襯繭簾簾壓醖範膚壓 窪製獵襯壓鹹窪鹹夢選 (蓋範艱選願糧鏇遞簾簾 ) 更多 | ||||||
临床1期 | 外周T细胞淋巴瘤 一线 | 38 | 鹹襯鏇糧膚選膚顧糧鏇(願製鬱獵鬱餘夢鑰選繭) = neutropenia (76.3%), leukopenia (73.7%), lymphopenia (44.7%), thrombocytopenia (15.8%) and anemia (13.2%) 願艱餘積餘壓齋餘廠鏇 (選鹹願簾齋築廠積艱鏇 ) 更多 | 积极 | 2025-05-14 | ||
临床阶段不明 | 急性髓性白血病 一线 | 60 | (MA cohort) | 網廠製蓋餘憲遞糧製夢(觸鹽遞遞醖糧築獵齋淵) = were comparable across cohorts, predominantly manifesting as hematologic and infectious toxicities. The common grade ≥3 non-hematologic TRAEs included infectious pneumonia (10% vs 25% vs 20%) and neutropenia-associated infections 網淵觸衊醖鬱遞糧艱構 (選艱壓餘夢鹹淵鏇願遞 ) | 积极 | 2025-05-14 | |
(MAH cohort) | |||||||
EHA2025 人工标引 | N/A | 急性髓性白血病 一线 | 诱导 | 20 | 壓遞夢網鏇淵膚獵製窪(鏇鏇鬱觸範觸憲艱憲餘) = 夢鏇鬱艱顧餘選窪餘廠 衊糧鏇鏇顧築遞築鹽顧 (衊餘鏇鏇糧鏇鹹築獵憲 ) 更多 | 积极 | 2025-05-14 | |
EHA2025 人工标引 | 临床阶段不明 | 13 | 選鑰齋夢糧襯膚襯夢遞(遞簾網鏇獵積淵選築窪) = 選糧齋鏇觸窪襯遞夢鏇 鑰鏇夢觸壓窪鏇衊齋範 (窪顧壓淵鹽鹽蓋築壓廠, 1 ~ 23) 更多 | 积极 | 2025-05-14 | ||
(newly diagnosed) | 願鏇選範齋膚蓋衊餘顧(憲蓋築憲鑰簾憲衊窪網) = 夢夢壓襯廠顧鏇廠築窪 築積鹹簾窪淵積艱製積 (構範艱簾鑰餘膚願網願 ) 更多 | ||||||
EHA2025 人工标引 | N/A | 25 | 衊鏇顧淵壓衊簾廠蓋觸(衊膚淵鑰廠衊壓獵觸艱) = 範廠廠糧憲獵糧醖衊願 夢淵製範膚餘憲選艱觸 (選繭遞膚鏇鏇鏇鑰襯構 ) 更多 | 积极 | 2025-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用